At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

In this virtual summit GEN invites you to watch a superb line-up of presenters covering key topics in the world of multiomics, spatial biology, and NGS.

The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...

Next-generation sequencing (NGS) has increased the speed, scale, throughput, and accessibility of sequencing, greatly accelerating genomic research. This progress has been aided by the development of ...

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

The US Food and Drug Administration (FDA) on Thursday issued new draft guidance meant to establish the necessary performance characteristics for genetic sequencing tests used to diagnose infectious ...

SAN FRANCISCO, Nov. 13, 2025 /PRNewswire/ -- The global next-generation sequencing market size is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. The next ...

Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip. Prognostic value of ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.